{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T16:35:42Z","timestamp":1793205342087,"version":"4.5.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"KBP BioSciences","award":["GPP 2022"],"award-info":[{"award-number":["GPP 2022"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>BACKGROUND<\/jats:title>\n                  <jats:p>Ocedurenone (KBP-5074), a nonsteroidal mineralocorticoid receptor antagonist, is documented to lower blood pressure in patients with stage 3b\/4 chronic kidney disease (CKD) with uncontrolled or resistant hypertension (BLOCK-CKD study). However, the efficacy and safety of Ocedurenone in subgroups such as Hispanic patients or those with stage 4 CKD, diabetes, or very high albuminuria have not been reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>A total of 162 patients were enrolled in the BLOCK-CKD study. The primary endpoint of these analyses was change in systolic blood pressure (SBP) from baseline to day 84. Prespecified subgroup analysis of SBP focused on demographic (e.g., ethnicity, age) and medical (e.g., CKD stage, diabetes, albuminuria, baseline estimated glomerular filtration rate [eGFR]). The safety analysis focused on changes in serum potassium levels from baseline.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>SBP reductions were consistent across subgroups compared with the overall study cohort. Placebo-adjusted SBP reductions were observed in Hispanic patients (\u22128.1 and \u22129.9 mm Hg for 0.25 and 0.5 mg, respectively, total n = 35) and patients with CKD stage 4 (\u22129.3 and \u221210.4 mm Hg for 0.25 and 0.5 mg, respectively, total n = 64), diabetes (\u22126.9 and \u221211.6 mm Hg for 0.25 and 0.5 mg, respectively, total n = 51), and very high albuminuria (\u221213.1 and \u221212.3 mm Hg for 0.25 and 0.5 mg, respectively, total n = 85). Changes in serum potassium were similar across all patient subgroups regardless of baseline eGFR, diabetes status, or degree of proteinuria. No cases of hyperkalemia required intervention or resulted in study discontinuation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Ocedurenone consistently reduced in SBP in all patient subgroups. Moreover, while small elevations in serum potassium occurred, they were not associated with Ocedurenone or study discontinuation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajh\/hpad066","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T17:46:36Z","timestamp":1689875196000},"page":"612-618","source":"Crossref","is-referenced-by-count":20,"title":["Efficacy and Safety of Ocedurenone: Subgroup Analysis of the BLOCK-CKD Study"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1183-1267","authenticated-orcid":false,"given":"George L","family":"Bakris","sequence":"first","affiliation":[{"name":"Department of Medicine, American Heart Association Comprehensive Hypertension Center, The University of Chicago Medicine , Chicago, Illinois , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y Fred","family":"Yang","sequence":"additional","affiliation":[{"name":"Chief Development Officer, KBP BioSciences USA Inc. , Princeton, New Jersey , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M","family":"McCabe","sequence":"additional","affiliation":[{"name":"Chief Development Officer, KBP BioSciences USA Inc. , Princeton, New Jersey , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Rong","family":"Liu","sequence":"additional","affiliation":[{"name":"Chief Development Officer, KBP BioSciences USA Inc. , Princeton, New Jersey , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan J","family":"Tan","sequence":"additional","affiliation":[{"name":"Chief Development Officer, KBP BioSciences USA Inc. , Princeton, New Jersey , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent J","family":"Benn","sequence":"additional","affiliation":[{"name":"Chief Development Officer, KBP BioSciences USA Inc. , Princeton, New Jersey , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Michigan School of Medicine , Ann Arbor, Michigan , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,20]]},"reference":[{"key":"2023101306283775500_CIT0001","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4103\/2249-4863.154630","article-title":"Resistant hypertension: an approach to management in primary care","volume":"4","author":"Yaxley","year":"2015","journal-title":"J Family Med Prim Care"},{"key":"2023101306283775500_CIT0002","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/heartjnl-2018-313599","article-title":"Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients","volume":"105","author":"Noubiap","year":"2019","journal-title":"Heart"},{"key":"2023101306283775500_CIT0003","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"key":"2023101306283775500_CIT0004","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.semnephrol.2014.04.008","article-title":"Prediction and management of hyperkalemia across the spectrum of chronic kidney disease","volume":"34","author":"Lazich","year":"2014","journal-title":"Semin Nephrol"},{"key":"2023101306283775500_CIT0005","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/13543784.2021.1985462","article-title":"An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension","volume":"30","author":"Pitt","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"2023101306283775500_CIT0006","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/HYPERTENSIONAHA.121.17073","article-title":"Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: results of the BLOCK-CKD study","volume":"78","author":"Bakris","year":"2021","journal-title":"Hypertension"},{"key":"2023101306283775500_CIT0007","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1161\/HYPERTENSIONAHA.120.15199","article-title":"Mineralocorticoid receptor antagonists for hypertension management in advanced chronic kidney disease","volume":"76","author":"Bakris","year":"2020","journal-title":"Hypertension"},{"key":"2023101306283775500_CIT0008","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"2023101306283775500_CIT0009","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1097\/HJH.0000000000002184","article-title":"Clinical characteristics, antihypertensive medication use and blood pressure control among patients with treatment-resistant hypertension: the Survey of PatIents with treatment ResIstant hyperTension study","volume":"37","author":"Carcel","year":"2019","journal-title":"J Hypertens"},{"key":"2023101306283775500_CIT0010","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12882-019-1348-4","article-title":"Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study","volume":"20","author":"Blankenburg","year":"2019","journal-title":"BMC Nephrol"},{"key":"2023101306283775500_CIT0011","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.kint.2019.04.032","article-title":"Considerable international variation exists in blood pressure control and antihypertensive prescription patterns in chronic kidney disease","volume":"96","author":"Alencar de Pinho","year":"2019","journal-title":"Kidney Int"},{"key":"2023101306283775500_CIT0012","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/ckj\/sfac234","article-title":"A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease","volume":"16","author":"Agarwal","year":"2023","journal-title":"Clin Kidney J"},{"key":"2023101306283775500_CIT0013","first-page":"S212","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors","volume":"21","author":"Epstein","year":"2015","journal-title":"Am J Manag Care"},{"key":"2023101306283775500_CIT0014","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"2023101306283775500_CIT0015","doi-asserted-by":"crossref","first-page":"425","DOI":"10.34067\/KID.0006782020","article-title":"Patiromer and spironolactone in resistant hypertension and advanced CKD: analysis of the randomized AMBER trial","volume":"2","author":"Agarwal","year":"2021","journal-title":"Kidney360"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajh\/advance-article-pdf\/doi\/10.1093\/ajh\/hpad066\/51099503\/hpad066.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/36\/11\/612\/52056787\/hpad066.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/36\/11\/612\/52056787\/hpad066.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T06:29:05Z","timestamp":1697178545000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/36\/11\/612\/7227048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,20]]},"references-count":15,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,7,20]]},"published-print":{"date-parts":[[2023,10,13]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpad066","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"value":"0895-7061","type":"print"},{"value":"1941-7225","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11,1]]},"published":{"date-parts":[[2023,7,20]]}}}